UCB GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.9M
Doctors Paid
68
Transactions
765
2024 Total
$353,983
Payment Breakdown by Category
Research$4.7M (96.0%)
Consulting$148,674 (3.0%)
Travel$35,655 (0.7%)
Food & Beverage$9,484 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 389 | 96.0% |
| Consulting Fee | $148,674 | 71 | 3.0% |
| Travel and Lodging | $35,655 | 124 | 0.7% |
| Food and Beverage | $9,484 | 180 | 0.2% |
| Education | $883.67 | 1 | 0.0% |
Payments by Type
Research
$4.7M
389 transactions
General
$194,697
376 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS | $1.7M | 0 | 130 |
| Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation | $1.3M | 0 | 81 |
| A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo | $724,958 | 0 | 48 |
| A MULTICENTER, RANDOMIZED, INVESTIGATOR - AND SUBJECT-BLIND, PLACEBO-CONTROLLED, TREATMENT SEQUENCE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH MODERATE TO SEVERE MYASTHENIA GRAVIS | $540,771 | 0 | 48 |
| PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE I | $137,135 | 0 | 23 |
| Randomized, double-blind, placebo-controlled trial of lacosamide for seizure prophylaxis in patients with malignant gliomas | $106,725 | 0 | 1 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH ANKYLOSING SPONDYLITIS. | $92,812 | 0 | 8 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active Axial Spondyloarthritis AXSPA without x-ray evi | $54,507 | 0 | 7 |
| MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOAR | $41,209 | 0 | 8 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active Axial Spondyloarthritis (AXSPA) without x-ray evidence of Ankylosing Spondylitis (AS) and | $25,445 | 0 | 10 |
| A MULTICENTER, RANDOMIZED, INVESTIGATOR - AND SUBJECT-BLIND, PLACEBO-CONTROLLED, TREATMENT SEQUENCE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH MODERATE TO SEVE | $25,125 | 0 | 5 |
| A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW-UP STUDY EVALUATING THE LONG-TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CONTROLLED-RELEASE CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY IN SUBJECTS WITH PARTIAL-ONSET OR GENERALIZED TONIC-CLONIC SEIZURES >=16 YEARS OF AGE COMING FROM THE SP0993 STUDY | $18,455 | 0 | 8 |
| Vimpat in children with status epilepticus or acute repetitive seizures | $7,350 | 0 | 1 |
| Phase 3, Multicenter, Randomized, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active Axial Spondyloarthritis (AXSPA) without x-ray evi | $6,441 | 0 | 4 |
| A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondylo | $3,687 | 0 | 3 |
| A multicenter, double blind, double dummy, randomized, positive controlled study comparing the efficacy and safety of lacosamide (200 to 600mg/day) to controlled release carbamazepine (400 to 1200mg/day), used as monotherapy in subjects (>=16 years) newly or recently diagnosed with epilepsy and experiencing partial onset or generalized tonic clonic seizures | $3,512 | 0 | 4 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Rheumatology | $44,554 | 6 | $7,426 |
| Dermatology | $30,481 | 18 | $1,693 |
| Pediatrics | $29,167 | 6 | $4,861 |
| Neurology | $28,699 | 17 | $1,688 |
| Emergency Medicine | $11,508 | 1 | $11,508 |
| Clinical Neurophysiology | $10,169 | 3 | $3,390 |
| Neurology with Special Qualifications in Child Neurology | $9,767 | 3 | $3,256 |
| Internal Medicine | $9,569 | 5 | $1,914 |
| Neonatal-Perinatal Medicine | $8,070 | 2 | $4,035 |
| Neurological Surgery | $5,910 | 1 | $5,910 |
| Pediatric Rheumatology | $2,156 | 1 | $2,156 |
| Neurocritical Care | $1,351 | 1 | $1,351 |
| General Practice | $1,241 | 1 | $1,241 |
| Pediatric Dermatology | $1,040 | 1 | $1,040 |
| Family Medicine | $1,002 | 1 | $1,002 |
| Dermatopathology | $14.46 | 1 | $14.46 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Angus Wilfong, Md, MD | Pediatrics | Phoenix, AZ | $17,920 | $0 |
| Joan Merrill, Md, MD | Rheumatology | Oklahoma City, OK | $17,280 | $0 |
| Dr. Dexter Morris, Md, MD | Emergency Medicine | Chapel Hill, NC | $11,508 | $0 |
| Megan Clowse | Rheumatology | Durham, NC | $10,056 | $0 |
| Kavita Sarin, Md, MD | Dermatology | Stanford, CA | $9,130 | $0 |
| John Stern, Md, MD | Clinical Neurophysiology | Los Angeles, CA | $8,800 | $0 |
| Shlomo Shinnar, Md,Ph.d, MD,PH.D | Neurology with Special Qualifications in Child Neurology | Bronx, NY | $8,000 | $0 |
| Brien Smith, M.d, M.D | Neurology | Detroit, MI | $8,000 | $0 |
| Dr. Richard Furie, M.d, M.D | Rheumatology | New Hyde Park, NY | $7,305 | $0 |
| Kenneth Gorson, Md, MD | Neurology | Wellesley, MA | $7,100 | $0 |
| Laura Schanberg, M.d, M.D | Rheumatology | Durham, NC | $7,000 | $0 |
| Johannes Van Den Anker, Md, MD | Neonatal-Perinatal Medicine | Washington, DC | $6,970 | $0 |
| Timothy Beukelman, M.d, M.D | Pediatrics | Birmingham, AL | $5,993 | $0 |
| Philip Gorelick, Md, MD | Neurological Surgery | Chicago, IL | $5,910 | $0 |
| Garth Graham, Md, MD | Internal Medicine | Kansas City, MO | $3,720 | $0 |
| Selim Benbadis, Md, MD | Neurology | Tampa, FL | $2,625 | $0 |
| Prof. James Krueger, Md, Phd, MD, PHD | Dermatology | New York, NY | $2,490 | $0 |
| Dr. David Wofsy, Md, MD | Internal Medicine | San Francisco, CA | $2,456 | $0 |
| Dr. Joseph Sirven, M.d, M.D | Neurology | Jacksonville, FL | $2,400 | $0 |
| Hermine Brunner, Md, MD | Pediatric Rheumatology | Cincinnati, OH | $2,156 | $0 |
| Dennis Dlugos, M.d, M.D | Pediatrics | Philadelphia, PA | $2,106 | $0 |
| Sung Lim, M.d., M.p.h, M.D., M.P.H | Rheumatology | Atlanta, GA | $2,013 | $0 |
| Andrew Blauvelt, Md, MD | Dermatology | Portland, OR | $1,750 | $0 |
| James Solomon, Md, MD | Dermatology | North Las Vegas, NV | $1,707 | $0 |
| Ricky Lee, Md, MD | Neurology | Wichita, KS | $1,518 | $0 |
Ad
Top Products
- Cimzia $4.0M
- Vimpat $159,558
Payment Categories
- Food & Beverage $9,484
- Consulting $148,674
- Travel & Lodging $35,655
- Research $4.7M
About UCB GmbH
UCB GmbH has made $4.9M in payments to 68 healthcare providers, recorded across 765 transactions in the CMS Open Payments database. In 2024, the company paid $353,983. The top product by payment volume is Cimzia ($4.0M).
Payments were distributed across 16 medical specialties. The top specialty by payment amount is Rheumatology ($44,554 to 6 doctors).
Payment categories include: Food & Beverage ($9,484), Consulting ($148,674), Research ($4.7M), Travel & Lodging ($35,655).